^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CCT301-038

    i
    Other names: CCT301-038, CCT301-38, CCT3-AXL-0038, CCT301038, CCT301 038, CCT30138, CCT3AXL0038, CCT301 38, CCT3 AXL 0038
    Associations

    News

    Trials
    Company:
    Exuma Biotech, Sunterra Biotech
    Drug class:
    AXL-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2ms
    Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=66, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Active, not recruiting --> Terminated; Adjustment of study strategy
    Trial termination • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
    |
    cyclophosphamide • CCT301-038 • CCT301-59
    2ms
    CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
    P1, N=9, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Aug 2025 --> Oct 2024 | Recruiting --> Terminated; Adjustment of study strategy
    Trial completion date • Trial termination
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL positive
    |
    cyclophosphamide • CCT301-038
    over1year
    CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
    P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Dec 2023 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL positive
    |
    cyclophosphamide • CCT301-038
    over2years
    CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
    P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
    Trial completion date • Trial primary completion date
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL positive
    |
    cyclophosphamide • CCT301-038
    3years
    CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
    P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd.
    Clinical • New P1 trial
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL positive
    |
    CCT301-038
    3years
    Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=66, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Mar 2035 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
    |
    CCT301-038 • CCT301-59